by Nyuykonge B, Siddig EE, Nyaoke BA, Zijlstra EE, Verbon A, Bakhiet SM, Fahal AH, van de Sande WWJ. Mycoses 2023, 00:1-8. doi: doi.org/10.1111/myc.13664
Summary: (1,3)-β-D-glucan is a panfungal biomarker present in serum of patients with eumycetoma. In this study, the authors used the WAKO (1,3)-β-D-glucan assay to measure (1,3)-β-D-glucan concentrations in the serum of 104 patients with eumycetoma who were enrolled in a clinical trial of two regimens of the potential eumycetoma treatment fosravuconazole. A sharp decrease in β-glucan concentration was noted after surgical removal of lesions at six months, but not during or after antimicrobial treatment. (1,3)-β-D-glucan concentrations were not predictive for recurrence and do not appear to be of use in determining treatment response to azoles in patients with eumycetoma.
